美波利祖马布
医学
嗜酸性粒细胞
哮喘
恶化
气道
免疫组织化学
细胞外基质
内科学
病理
嗜酸性
支气管热成形术
胃肠病学
肺功能测试
肺
弹性蛋白
肺功能
嗜酸性粒细胞增多症
嗜酸性粒细胞颗粒蛋白
免疫学
支气管镜检查
呼吸道疾病
作者
Isabella Drummond,Juliette Phillips,Ravinder Dhillon,Jennifer Naftel,Wint Soe,Paddy Dennison,Rocío T. Martínez-Nuñez,Jonathan Ward,Cornelia Blume,Emily Jane Swindle,Hitasha Rupani
出处
期刊:The European respiratory journal
[European Respiratory Society]
日期:2025-09-27
卷期号:: PA4609-PA4609
标识
DOI:10.1183/13993003.congress-2025.pa4609
摘要
Background: Mepolizumab, an anti-IL-5 biologic used to treat severe eosinophilic asthma (SEA), reduces exacerbation and improves asthma control. Airway remodelling (AR) is associated with persistent symptoms and lung function decline. Limited evidence exists investigating the effect of mepolizumab on AR. Objective: We aimed to investigate the effect of mepolizumab on AR in patients with SEA, hypothesising a reduction in AR markers and an increase in epithelial barrier repair following 6 months of treatment. Methods: Bronchial biopsies from 20 patients with SEA were collected by bronchoscopy at baseline (T0) and 6 months (T6) post mepolizumab ( NCT05144087 , GSK funded, investigator led study). 14 (70%) paired biopsies were analysed using immunohistochemistry and movat’s pentachrome staining. Clinical and lung function data were also collected. Results: At T6, there was a significant reduction in exacerbations (median AER: T0 5 [IQR 4-7], T6 0 [0,0]) and significant improvement in asthma control (ACQ: T0 2.8 [IQR 2.1,3.1], T6 1.0 [0.3,2.1]) and lung function (FEV1/FVC: T0 0.60 [IQR 0.57, 0.66], T6 0.64 [IQR 0.58,0.75]). In bronchial biopsies, submucosal eosinophil counts (P ≤ 0.05), extracellular matrix deposition of collagen and elastin (both P ≤ 0.001) and goblet cells (P ≤ 0.01) were significantly reduced. Specifically, collagen-1 was reduced (P ≤ 0.05). Finally, a significant increase in e-cadherin (adherens junction marker) (P ≤ 0.0001) was observed. Conclusions: In addition to improvement in clinical parameters, mepolizumab reduces histological markers of AR and facilitates epithelial barrier repair in patients with SEA.
科研通智能强力驱动
Strongly Powered by AbleSci AI